Traitement anticoagulant initial de l’embolie pulmonaire

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Revue Des Maladies Respiratoires

• Publication date

  2011-02-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/J.RMR.2010.09.027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• [Pulmonary embolism: role of the diagnostic and prognostic scores].

  2010cited by this paper
• Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.

  2010cited by this paper
• [Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients].

  2010cited by this paper
• Vena caval filters for the prevention of pulmonary embolism.

  2010cited by this paper
• Acute pulmonary embolism.

  2010cited by this paper
• Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues

  2009cited by this paper
• Diagnosis and initial treatment of venous thromboembolism in patients with cancer.

  2009cited by this paper
• Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases

  2009cited by this paper
• The Inefficacy of Enoxaparin Prophylaxis in a Patient With Congenital Antithrombin Deficiency

  2009cited by this paper
• Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry

  2008cited by this paper
• Heparin-induced osteoporosis and pregnancy

  2008cited by this paper
• Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Systematic Review: The Trousseau Syndrome Revisited: Should We Screen Extensively for Cancer in Patients with Venous Thromboembolism?

  2008cited by this paper
• Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism

  2008cited by this paper
• Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials

  2007cited by this paper
• Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia

  2007cited by this paper
• A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism.

  2007cited by this paper
• Cost–effectiveness of bemiparin in the prevention and treatment of venous thromboembolism

  2006cited by this paper
• Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular- Weight Heparin for Acute Treatment of Venous Thromboembolism

  2006cited by this paper
• Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.

  2006cited by this paper
• Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis

  2005cited by this paper
• Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.

  2005cited by this paper
• Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.

  2005cited by this paper
• Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

  2005cited by this paper
• Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia.

  2005cited by this paper
• Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

  2004cited by this paper
• Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism

  2004cited by this paper
• Acute pulmonary embolism.

  2004cited by this paper
• Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.

  2004cited by this paper
• Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

  2003cited by this paper
• Cancer and Thrombosis: Mechanisms and Treatment

  2003cited by this paper
• Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

  2003cited by this paper
• Postpartum Bone Mineral Density in Women Treated for Thromboprophylaxis with Unfractionated Heparin or LMW Heparin

  2002cited by this paper
• Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series

  2002cited by this paper
• Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies

  2001cited by this paper
• Heparin-Induced Thrombocytopenia

  2000cited by this paper
• Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.

  2000cited by this paper
• Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.

  1999cited by this paper
• Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group.

  1998cited by this paper
• Clinical presentation of heparin-induced thrombocytopenia.

  1998cited by this paper
• Early versus Delayed Introduction of Oral Vitamin K Antagonists in Combination with Low-Molecular-Weight Heparin in the Treatment of Deep Vein Thrombosis

  1998cited by this paper
• Vena caval filters for the prevention of pulmonary embolism.

  1998cited by this paper
• Fatal Danaparoid-sodium Induced Thrombocytopenia and Arterial Thromboses

  1998cited by this paper
• A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.

  1997cited by this paper
• Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

  1995cited by this paper
• Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.

  1992cited by this paper
• Antithrombotic therapy for venous thromboembolic disease.

  1992cited by this paper
• Subcutaneous Heparin Compared with Continuous Intravenous Heparin Administration in the Initial Treatment of Deep Vein Thrombosis

  1992cited by this paper
• Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.

  1986cited by this paper
• Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.

  1979cited by this paper
• Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

  1960cited by this paper

• Comparative study of the anticoagulant powers of the aqueous macerate, ethanolic macerate and aqueous decoction of the leaves of Uvaria chamae P. Beauv. (Annonaceae)

  2021cites this paper
• Nouveaux anticoagulants oraux dans le traitement curatif de la maladie thromboembolique veineuse

  2013cites this paper
• Épidémiologie des TVS des membres inférieurs

  2011cites this paper
• Maladie thromboembolique veineuse : une nouvelle série arrive !

  2011cites this paper